HRMY - Earnings call transcript Q1 2022 | Harmony Biosciences Holdings, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning. My name is Ashley and I will be your conference operator today. At this time, I would like to welcome everyone to the Harmony Biosciences First Quarter 2022 Financial Update Conference Call. All participant lines have been placed on mute to prevent any background noise. After the speaker’s presentation, there will be a question-and-answer session. Instructions]. [Operator that be advised conference today's be recorded. may Please Instructions]. [Operator call Luis Sanay, I will of to the turn now Head over Investor Relations. Please ahead. go

Luis Sanay

operator. performance and and everyone a business today Harmony Good for provide first you, Biosciences financial us review as thank XXXX quarter update. joining we Thank you morning,

to the of discussion the non-GAAP financial we and press cycle, non-GAAP Before to slides I our today, our stage of that life performance. represent everyone encourage section start, our including financial the release reconciliation a website GAAP go accompany this our At to Investors to better measures. business results find underlying of believe we

Officer; on Dayno, Chief Financial and CEO; Our call Jacobs, John Officer. Dr. today's Chief President Jeffrey Jeffrey Officer; and Commercial Sandip presenters Medical Kapadia, are Chief Dierks,

on Slide Moving X. to

to we risk reminder, to These our would and Jacobs. expectations which and you turn over now uncertainties, actual making our forward-looking call encourage and to I risks be I the beliefs. on John? based will consult like details. certain statements in our are may materially. factors a our today, current statements CEO, subject filings additional the differ are to for As results SEC referenced John

John C. Jacobs

call thank for you you Thank and Luis joining today. our everyone conference

milestones. During key with three continued progress the first and to strategy two quarter our pillar across pillars growth we execute on achieving all three

heard momentum me about excited best forward the see you our we we say making previously, in and are have yet. are year We XXXX business to the as looking

XX% QX delivered increase is performance. on quarter with of three quarter. pillars in growth a our a minutes WAKIX. which strong for revenues the highlight million, the on of like XXXX commercial performance Starting quarter the one progress each strategy one to take would of our to the XXXX with WAKIX few I context pillar year-over-year we of Now $XX.X of to a optimize In

for WAKIX net since $XXX important November We of XXXX. million our milestone an in in surpassing also launch revenue cumulative reached

Officer quarter strong will call. reflects in payer our prescription detail seasonal in Commercial with further during Jeff Dierks the performance and remain our patient Chief business of demand starts the new quarter month in over the first The representing discuss March fundamentals in performance strongest year. anticipated topline WAKIX underlying dynamics a which later

For and the remainder the the quarter-on-quarter growing underlying growth due opportunity strong of in demand year, and WAKIX expect large we narcolepsy. to for

Let's utility move two clinical beyond pillar of on narcolepsy. is to to which the expand WAKIX

reached for successful if towards living Phase this indication or WAKIX. announce idiopathic IH. X will are advance that of innovative week This program registrational yet of to we Last quarter we milestone We're the hopeful trial people were and for lead excited diseases. with hypersomnia rare delivering these pleased to neurological another Pitolisant in our therapies we next the to health efforts improve initiation the

broad intention metabolic expand three, and pillar development take portfolio assets hyperphagia, It's stages will a acquiring during effect launch consider. business in with clinic With the pre-clinical HBS-XXX both to the the three Prader-Willi have Pitolisant HBS-XXX can Harmony neurology hypersomnia. we WAKIX. under often able of Furthermore, so Dayno after on flexible idiopathic Prader-Willi advancing our new call. through both we're asset to be parameters. IH WAKIX in rare range history program are to now neurological lifecycle. of stage gain, other programs proof including of we and position syndrome, later is in And portfolio develop types company our prudent in thoughtful to into in other strategy. explore and/or to this myotonic and of can concept clinical assets we early more execute Dr. and where for later infrastructure. the we our to in this the finally and And expertise we share what time assets we its and Over second of the deals symptoms existing are beyond we're dystrophy, early our seeking including in assets WAKIX on the Jeffrey syndrome way in conditions time To the is journey this, our a and this on development acquire stage to leverage achieve good potential beginning important a that across

Harmony. extremely We position I this continued to growth with billion progress future. via am potential are the we next a based our what remain foundation, and build $X strong and We years at in can truly regarding our about conditions. a being puts to which potential additional with the am Overall strategy current for doing plus coming And on confident market here are that optimistic the on strong achieve the execution position franchise WAKIX and narcolepsy intently on make in pillar as us excited indications. very pleased our I focused financial three in

of health Commercial broad Our with Dierks have vision people is innovative Harmony’s Jeff? Jeff with of neurology leading to evolve the living into call the over to rare other like and potential turn would that portfolio diseases. assets to Chief company I to neurological Officer. a a now improve the

Jeffrey M. Dayno

Net In the $XXX XX% we a was our net made revenue, business of launch. increase quarter years achieved net and narcolepsy first million both surpassed quarter since that was in XXXX. business John. first the million, for less revenue Thanks than $XX.X X.X XXXX in advancing milestone QX from significant cumulative our of approximately in first representing strides We revenue fundamentals. underlying in the quarter

benefit and unmet also a profile speaks of market. continues resilience reflect how narcolepsy risk to the Our WAKIX the launch since our not strong aligned overall commitment team medical only the with of in to but needs performance significant

experienced average increased which X,XXX is of of the Now like to of fundamentals first seasonal approximately payor first once anticipated each quarter the first care for a program number dynamics the The reauthorization first of continued quarter. in years moving the on the X, I'd specialty and of underlying year. quarter XXXX. business assistance our in WAKIX reflective on managed that patient two highlight few in of previous in same our to yearly seasonal Slide the the launch products patients our drove reverification, We typical growth branded quarter dynamic to

smaller As patients reauthorizations we're on our now did in majority versus to sought mostly patients, criteria in a through to year patients patients treatment of not insured and not delays commercialization larger patients previous starts, our access a some percentage meeting immediate of third of the although coverage, years. reverification of their government in due of Due our vast patients subject continue than the strong third continuing experienced payor and are approvals market are to new our patients approvals. majority support. A prescription financial party group patient

requirements continued some experienced pay Additionally, the on these Absent free no would prior quarters. free eligibility similar growth patients and government longer as average patient program goods. one-time good assistance meet and did have patient not program event we patient

momentum month Moving over and demand business new month as in growth our topline March patient of and confident in we performance line a continued head QX. forward and strongest we are starts new this prescription starts into strong WAKIX. in of in demand and represented patient and of prescription provide top year performance our

the Turning meaningful more in treatment. in available in repeat become have to WAKIX growth treatment growth of in other prescribers prescriber WAKIX. X quarter We patients narcolepsy base and the saw or new they a written clinical scheduled who professionals adoption writers. opportunity to a further since majority of adult The been for our a narcolepsy of and as prescriber traditional have as of broadening our have demonstrating I both for prescribe base depth growing we pleased XXXX launch. the further narcolepsy well writers they We're WAKIX if are first prescription week prescribers narcolepsy. observe both the reluctant with for in healthcare or mean breadth continued

their continue in treatments. see and sales healthcare the were person quarter XXXX in-person than by in professionals concomitantly of More quarter. WAKIX narcolepsy speaks first field provides utilization of and [indiscernible] prescribers. both and an territories We communicated the what end their in as narcolepsy type call. in and end quarter one the monotherapy staff all positions The engagement for first existing education in further the the WAKIX team from new patients April office prescribed of to engagements trained, to other hired, broad with well WAKIX growth of We quarter XXXX. of as XX% saw We with in being two expanded as and completed and engagement our we field an field access drive earnings increase the the with all line fourth quarter to of with first Xst expansion in for type sales last by our and both increase for in towards opportunity sales team our the second an in of opportunity

continual the We In expect strong our following with $X in access of and the number benefit now professional field extend the confidence to at our head for importantly broadening continued WAKIX line about team we quarter reach our ability I'm in and demand the development to WAKIX half strong The of in of lives with on average field in the this of expansion person team continue for and the clinical a us summary base, making I'll and areas; being for But patients. franchise excited our place expansion fundamentals into universe. access to WAKIX and health most difference our in in top grow the Dayno all of billion team as one opportunity. see affirm broad treating patients sales of in strong potential narcolepsy the our to our depth by gives second type education people confidence update performance market is in of over the added WAKIX, for on earliest. the the to our as care field the I'm Dr. momentum narcolepsy. narcolepsy XXXX Increased expanded Jeff. excited WAKIX sales business market sales of Jeff to in healthcare second WAKIX. living prescription and continued plus prescriber an breadth the to underlying growth offices access improvement presentation the program. turn professional

Jeffrey M. Dayno

clinical our am development Thanks two and to Jeff update our programs pillar pillar on an of to utility and three growth of morning clinical expand I the everyone. strategy Pitolisant. good provide pleased

we for investigators treatment to as after trial. in participation Pitolisant have primary design registrational study There's X. to be working with objective a with The assess efforts patients and XX randomized patients families We U.S. as from with scale the brain patients last the investigating Epworth Key the appreciate clinical communities withdrawal adult found in with treating include as blind endpoints X trial placebo of community known secondary hypersomnia measured by utilizing we the Slide and that off, on patients. fog are First as the from The in IH is evaluated global INTUNE of in Highlights are or IH trial and IH. IH in announced of excessive the sleepiness of patients initiation also of with the placebo of Study. or daytime been compared a and patient pleased impression sites our up the about with. Pitolisant be trial Approximately of and patient measuring efficacy patients medicine participating with over ESS. excited of trial the sites and is double week the of Pitolisant cognitive The is Pitolisant the of can or we and trial Phase change. trial adult IH EDS to are hypersomnia study been assessment in XXX target about in the also Sleepiness we with severity start this referred the will of will actively this enrollment activities. assess clinical interest impact in idiopathic at what commonly sleep Scale much controlled IH baseline the our this function by pace XX complex both symptom XXX with and on idiopathic safety

the on to another We are unmet indications Study on need. with We could calls. new WAKIX forward neurological for the for excited medical INTUNE updates patient and potential providing INTUNE to significant population look lead about Study the future if positive rare disease next

are which X. Turning lifecycle or pipeline for to our other our management Slide Pitolisant programs shown on Slide

this data year. made good in track and second progress of the patients trial We line proof with Phase on half of our have Syndrome Prader-Willi or in X top are for concept on PWS

For new X with in XXXX. in and X enroll DM Phase anticipated activate top line our X trial continue sites patients dystrophy myotonic data patients or we type with to

words melanin antagonist few early Lastly, on X asset stage shown hormone a our a as on receptor which is concentrating HBS-XXX, Slide X.

and as as one and with other control on the as on as an hormonal of objective hyperphagia country of located Biology model study parameters concept potential labs gain track of control of in working a this a initiate are as in to feeding well its and of neurons impact key of function proof be in Prader-Willi mouse energy WAKIX top the later utilizing MCH established utility well MCH the the study this hypothalamus and symptom Syndrome. metabolic metabolism. center We are of behavior autonomic assess of proof concept The for to year. the pre-clinical HBS-XXX will are

Phase an out In provide are pre-clinical idiopathic closing concept which in financial indication with for with an Thank initiation later neurological medical this and turn performance. proof update to new time a registrational the you for WAKIX of to development study I'll this our on rare trial. the over adult data excited unmet call would a our line we patients our now on Sandip. of clinical positive of programs our for move and need. hypersomnia to If INTUNE read this Sandip the us year. will potential update X study about We accelerates CFO, Kapadia closer disease another

Sandip Kapadia

morning our morning where press quarter of our you results. we our financial find good and XX-Q first XXXX will filed Jeff you and details This release operating and the Thank everyone. issued

quarter first performance XX. and is on X, also XX, Our shown Slides

of from We how with we're income the and started growth I'm flow balance continued for outlook to and while generate revenue show strong and pleased year-over-year year. the operating we the operations. cash continuing XXXX seeing to the momentum

in quarter. This reflect to of and growing net first of demand WAKIX represents continued the million for in a we growth XXXX revenues For the quarter million reported XX.X XX.X compared prior year the WAKIX. for XX%

did the the well in expected As typical trade quarter. of dynamics higher reduction early payor impact gross the resulting deductions net inventories see to seasonal quarter as first as during in part we in the of the

balance We dynamics the of expect these to year. the normalize throughout

first in in pipeline WAKIX and be operating the The of commercialization During operating expenses quarter million XX continues to prior were million compared our by to programs. quarter. driven XXXX advancement growth the expenses of our XX.X year the

per net million adjusted profitability improvement as As reported quarter. operating we the a quarter first we million XX.X compensation, or align reconciliations in prior operating income prior non-GAAP quarter underlying million GAAP adjusted excludes non-cash result, Please have Non-GAAP XXXX We per our XX of income this reflects or updated better we Starting stage year XX.X of items a first non-operating had for with Thus one-time commercial income see in quarter. items compared of interest companies. the to to are along in to with effect expense, release net these was other non-GAAP better diluted depreciation, items. measure the biotech to reconciliation XXXX year and share for business other amortization, the when our believe $X.XX the tax XX.X million compared press non-recurring $X.XX stock measure. diluted share non-cash, performance based excluded. updated the

operations from quarter equivalents and we cash XXX.X During March of in generated of with cash million and million ended XXXX XX the cash of first XXst. approximately quarter the as

to quarter since also Bioprojet. $XX milestone cumulative which net a launch our partner surpassed the million XXX of During we WAKIX triggered million final payment revenue

we growth balance quarter-over-quarter momentum of we revenue net the have for and payor business strong navigated have earlier XXXX. ahead expect the Looking and dynamic

in successfully continue increase as to to expect an strategy. execute we pillar our SG&A investment on We R&D three and growth also

balance based turn to So X the additional in that plus to capital reinvesting development back operate to believe revenues, with call conclusion has to our We potential a and narcolepsy program we the his our with indications be We strength to billion WAKIX assets. prudent continue acquire like and to growing in fund solid closing that a ongoing to expense John. John coming other from position And remarks. of access additional I'd forward a franchise controls, look and capital. on the for years. sheet,

John C. Jacobs

fundamentals pillar putting Thank be good business to In three our in execute growth yet you strategy position strong, summary our in a make continue company history. Sandip. our XXXX us to and best year

strong sustainable planned on the of to differentiated a new term unique with the Our Thank beyond to today. to company To our to We to organic the back questions. demand turn and continue joining intent narcolepsy is in we forward Harmony narcolepsy the open will and Operator with and our growing assets the clinical things over look utility operator populations growth our this execution I please programs therapy beyond WAKIX commercial with year. our potential. innovative to to throughout portfolio Q&A remarks neurology sales expanding and meaningfully rare via for leading to goal call session. to acquire product. continue vision advance our you into evolving facilitate bring good for you concludes patient of expand call this This the long help of now updating progress WAKIX WAKIX can to new the

Operator

with open. Instructions]. [Operator we'll first line you. our And Please Brill your Thank Raymond question go ahead, take the from James. Danielle is

Danielle Brill

increasing adds historical you forward? back increase the prescriptions? to morning to or should just on this the moving And back range patients Thank on WAKIX then good what on said this patient new that Was so in be XXX delays an coming reauthorization clarifying outlook thanks XXX anticipating for you. was with we being line the by driven couple and I have guys, March for so a much question. Hi and questions strong.

John C. Jacobs

QX we to product dynamics for a question. Thank your have I little so bit that. Danielle, very experienced seasonal to we color your QX Jeff actually. and we strong over QX this demand hand add in John. to for is Jeff. was organic as more question you in than actually stronger Dierks predicted our But don’t why what

Jeffrey Dierks

Good morning Danielle.

So with represented demand prescription the starts. and to respect in top new March, of terms month patient March strongest line

average the organic growth prior forward question adds that second in reauthorization. So we forward-looking guidance, patient new versus do to although this your demand question. forward, answers about in the returning moving anticipate moving is And we're I XXXX. not your providing patients hope net quarterly

Danielle Brill

thank Yeah, you.

Operator

will our question Howerton Please Chris Jeffries. we and from next take Okay, with ahead. go

is line Your open.

Chris Howerton

Hi, I patients great. much questioning some average would thanks time taking be curious maybe useful? refill so to questions. information the be of could of you of Hey, the something in on maybe WAKIX kind of terms drugs for me. And around of durability from similar on guess provide vein know then I'd if or rate that the just a payers the terms dynamics demand from you Jeff just were -- and guess more little moving forward, wondering you add if the guess headwinds on that of clarification said meeting patients clarification relative articulated? you I that assistance for payment. guys from was the not I me, I in could government I

John C. Jacobs

Jeff, question ahead Go that Chris? want to take you from

Jeffrey Dierks

for Chris. sure. the Yes, question, Thanks

communicated this to discontinuation average in category with and range XX-months commercialization respect it's the consistent average expectations XX%. year care enrolling time early professionals. between And, of right is are the what is in from falling seeing, and that we've our the in what on durability from drug, the range very of third is still it's publicly with although seeing, So we're we're products and what patients WAKIX XX% on for rate health middle at of that terms

the community. government being with one on we're patient, the is narcolepsy pay with your of about payor the government how to so context respect product question the by With pleased to the XX% respect right, pays dynamics very is So well overall second received mix.

were we've into, Right, in to extremely that year had return we're to patients optimistic potential growth. for think that the pleased seen. new really QX, likely number the given WAKIX and payor continuing and to need was assistance remain programs kind they were premiums Medicare my help provide of refills similar insured And third fewer absent the experience first experienced. But very terms add size new strongest Assistance which characterize financial to to data a February drug. so some every from wanted Chris, this reauthorizations of Reauthorization, number and the metric and base talk enough through copay is better reauthorization have and line quarter, But for those funding independent we're process, quarter would of into the is reauthorization plus true And March in and starts the excited and we prior on seasonal stronger in just dollar we a March. Danielle, growth of average some opportunity. patient insurance WAKIX party or billion WAKIX on And that Then one I treatment, of month about approximately process, Obviously, average assistance. patient resulted didn't average with that we meet we've is patients terms of patients government to in about of of and X,XXX sure active patients continue in confident Patient in number their annual we're And criteria those of with year. patients prior demand patients or reflective as exiting ultimately on in top on the I over I with to our performance as dynamics of on starts we you coinsurance X,XXX. patients the response the that didn't patients this about the kind it's exited demand. we So confident is but eligible franchise. test anticipated quarterly receive of we assistance that, also thing, seek because quarters. patients an diagnostic anticipated on a financial about patient shared I'm pushed get looking some And independent annual first

growth due is these to the So less first the in patient dynamics. anticipated rate QX slightly average quarter of

a with these we've heading us year. that momentum you to give just got rest outlook of behind performance, kind So the of are great very, we're a really great for events very we've our got one-time sense and pleased into the QX,

John C. Jacobs

the of in QX than and was in lead QX. best drug indicators Right organic Jeff, demand it one for higher the is our was

the anticipated are as dynamics seasonal these really and strength our we is into of So business robust forward XXXX. move

Chris Howerton

don't really helpful. I That's if And what able tell Jeff, in was of patients number you're the to at XQ end terms of but know the exit us, -- active patients?

Jeffrey Dierks

haven't we Yeah, a up and data. that disclosed looked with at back Chris, Brian, we and information circle honestly, But call. haven't that follow even you in

Chris Howerton

No problem. I really and pride, appreciate again, it. great Thanks everyone.

John C. Jacobs

Chris. Thanks,

Operator

And Fitzgerald. our ahead. with next we'll go Please Charles from Duncan take Cantor question

Your line open. is

Charles Duncan

John quarter. morning, and in commercial the for And and question. progress Good Thanks taking on congrats the the Yeah. development team.

first quick quarter? would sales impact Jeff then guideposts impact? the learnings yeah, you about talked full first a earliest secondarily, why force year guess, from wondering say the little maybe you question of given I'm regarding best you quarter, earliest of I I'm XXXX, mentioned year And if wondering see, measure how the for expansion, Let's and I half we guess Dierks, bit at can the that for provide the you second at kind

John C. Jacobs

Sandip, to answer year Charles first? full guideposts, you about was asking want question did that

Sandip Kapadia

both through but the the net some of what providing have of would Yeah, we strong more growth. we're can quarter-over-quarter sure. details. not forward-looking about growth year, Charles, is balance the in We will terms fundamentals, the know business guidance, you get for got sales expect, Jeff of and patients say I as good

March momentum So forward. expect, we're and that seeing we certainly coming going out continued of

in about of So our to Charles, I our impact And for hopefully expectations a year. second gives that of question force your was want Jeff you expansion. do you the bit think that? context terms little Dierks, sales of handle

Jeffrey Dierks

it's Yeah, for the from you. absolutely. to Thanks great question, hear Charles,

shared, depressed expansion the half to second of So be and of relationships. to the of takes team benefit the as difficult reach we obviously, hired, positions completed the all all the expansion to simply time see we've because a April in us of sales X. territories in about in environment, We're by trained, year, this and to it by our targets. able for we with And know their COVID expecting we expanded it's sort obviously, our build XX%

shared are is about interactions in what our of person. So, we've XX%

you So would six, calls eight a from for it an change education. take through seven, anticipate behavior a to likely may individual prescriber

just simply really if quarter and we're the of we're likely start those helps. the and the geographies, opportunity learn with uptake of and half allowing at earliest expecting build their year starts healthcare prescription get second new in to impact relationships, the those that second the professionals patient to out new So that educate

Charles Duncan

Got it. ahead. I'm sorry. Go

John C. Jacobs

No, go ahead please.

Charles Duncan

to you SUNOSI has Yeah, narcolepsy versus WAKIX positioning then changing one SUNOSI? they change dynamics, cover that have the given company with is do market given SUNOSI acquired and competitive quick the anything on commercial with product, regard of dynamics, that regarding but I follow-up see marketing to market regard landscape and and currently don't effort commercial Thanks.

Jeffrey Dierks

growing a only July non-scheduled market. Thanks differentiated has Charles. in novel market I the the the branded of the an segment for is my active In since been histamine. option. believe for question, by profile, meaningfully offering don't option perspective, of SUNOSI changes see narcolepsy treatment the WAKIX treatment any It's XXXX. available, We a product mechanism around working

And and our WAKIX population, believe belief with product in products. we brand. QX unmet supports about really the really large of plenty for strong We're branded we're the excited multiple need, differentiated demand seeing opportunity WAKIX, for the given that profile the the really in for there's significant long-term undiagnosed a and so patient room

Charles Duncan

Cool. Thanks for taking my questions.

John C. Jacobs

joining thank It's And covering analyst. you today. Charles for just have wanted to us. great aboard welcome as here And you a to you

Charles Duncan

here. Excited thanks. be to Yeah,

Operator

Piper question next Please our take go Sandler. Amsellem we'll And from David ahead. with

open. Your line is

David Amsellem

thanks. Hey,

a just couple. So

because quarter you've did like if apologize type you with are more first even takes prescription does talk look to that First, but label time idiopathic seasonal in question. previous get on can and us script it a what a first filled, speaking, the a narcolepsy missed what of whether and seeing you the this, generally in So can mix And that repair about I you typically dynamics take Thanks. type between from guess seasonal the a mind of patients use where any you secondly, here walking that, of hypersomnia NIH? that are just [ph] at look that's and are little just the away then away off I getting they're ongoing? in one the like if dynamics got and you two actually, sort just bit evidence or I'm refresher is any of getting give what hurdles,

John C. Jacobs

I in in David, significant to request when And mean, being a the XXXX, to on it patient actual efficiency launch when an since obviously, it we've of improvement product. comes convert prescription fill, to into be you seen additional to efficiency able color in seen may rare since And to that. a think Dierks some launch. that's we've over XXXX, that want a I launch in in to improvement remarkable add orphan anticipated But time. time Jeff

Jeffrey Dierks

point, the orphan Dave than your time look seeing industry the thanks at to in relatively John, other pharmacy fill. filled specialty seen when have with you are time getting we're to point that better And, your rates other products a benchmarks we Yeah, efficiencies rare to the prescription some there. and

single mixed one level in chronic question industry fill every and the is oral consistent it's So standards. a is There seeing rates or what With the that don't on oncology of for impact an any at prescription with time and second type with some type whether on we abandonment. product has abandonment believe for we're disease, two. our abandonment

type us and prescriptions their office. what about we're type in presenting for in our XX% new one for presentation seeing XX% type half They're type we're two, with coming about are of telling mirrors narcolepsy, clinical which seeing physician's two. about one of the patients sort in So of

So broad opportunity. able tapping be WAKIX narcolepsy is eligible to into really and that

treatment WAKIX narcolepsy. to professionals that with hear We is that from continue adult healthcare for an patients all appropriate option living

And so community. the kind in of in I KOL data terms ask Dayno what from assist seeing in maybe IH, Dr. is to vetting of and And there. the we're maybe interest out can,

Jeffrey M. Dayno

for question. thanks David, the Hey, sure. Yeah,

hub. We from that terms obviously, do a of registrational and patient the new now interest hypersomnia, and been In towards But Pitolisant, our and terms study potential for of into indication and we requests know doing is prescription trial, see the that in there's the lot focus a terms of on IH IH. or of idiopathic working sleep Phase coming medicine in X the WAKIX community community.

Study are we've we IH, aware trial. interest Pitolisant of in on So been the registrational doing for and and the INTUNE that focused growing

David Amsellem

great. guys. Thanks, Okay,

John C. Jacobs

Thank David. you,

Operator

Corinne we'll Sachs. go take our Please Jenkins from next And question with Goldman ahead.

line Your open. is

Corinne Jenkins

are Yeah. new of as Good a expand bit about March, are dynamics spoke just growth, the driving that? could on that what that in the saw you morning, everybody. drivers I you patient on was strong that if any the have you growth some organic for you visibility hoping

John C. Jacobs

we saw strong any on product really QX, some for commentary Jeff, you because and mentioned March. that organic demand the in

the a color context can. that little drivers have about more we a some of and question So you if on

Jeffrey Dierks

increase increased what I saw of sales question the we than XX% team person for more March. in our Thanks Sure. engagements mean, in is Corinne. to number the the in field with

still terms we're And launch education dealing and January. headwind in this than we've our COVID So greater was it the in it access our we of sort ability in know, and professionals. healthcare with given early to was been that kind in of per se of February March

in was So driver. that to healthcare professional foot some traffic in likely I started think We that foot in a following and February. increases saw educating in staff January traffic March we patient see their and lower person the engagement,

decision. the to staff, our need pharmacy in entire the healthcare there's portion the a on base, and increasing the as a product, that depth the are specialist there's new be I educated with it, coordinator us prescription. the optimal of our really on be starting But representatives to the the back have I prescribers, process counseling that engagement getting very this obviously, specialty third is office, WAKIX with think drivers, to educating or in for office professional think and an they to There's prescriber second those billing make in this able the of growth reimbursement a all opportunity patient much meaning nurse experience. sure see a as as and we patients educational So continue well

optimistic So community. the the and I with Corinne year of going we're looking March, in saw very narcolepsy for make -- difference continuing think really remainder that the to momentum pleased of to we forward in the we're a we're terms in and

John C. Jacobs

month prescribe adding of consistently correct. the of on become and strongly additional each prescribers, very who of new we're continue each vast quarter repeat well, Jeff top whom as to base prescribers and and the drug prescribers to many majority

Jeffrey Dierks

Correct.

Corinne Jenkins

of to And then to writing with much hand the office maybe need you with to psychiatrists visits a your force anything engagement is do sales have holding you as of specialty number pharmas? change you last whole point smooth care prescriptions, same for may have or and the there primary around kind aren't who order prescriptions as the amount narcolepsy the target of respect expand the to not or the you to need in process expect to experiences

Jeffrey Dierks

Corinne right, a more within field someone that's there's and team a have have familiar we able obviously, great is education been support novel if going help and with necessary think education that distribution on specialty you've reimbursement. to a offices, a pharmacy there team I got education every for and field And model, through we new that the expanded, that's educated mechanism. a out with you're it's product. reimbursement But the sales manager Yeah, There's product, likely office. less

staffed have a We hub. patient fully dedicated and

be service on care additional future that that surround of bring able that we can anticipating have that some offices, very of to these have journey really some may great it. We've to some appropriate success sophisticated educating sure very So of board similar We a really we the existing we with white we're doctors in all make touch know there but likely in points. these and glove have and time and the a office be in that investment psychiatrists do sort resources quarters. in continue new primary writers to right seen we

Corinne Jenkins

you. thank Great,

Operator

[Operator Instructions]. Francois Brisebois Please go And from Oppenheimer. next ahead. with question we'll take our

Francois Brisebois

for thanks questions. the Hey, taking

for the and get the patients, it just rare. little indication. true feel a So like a more commingling But wondering, to be trying of to seems I there IH to just IH, XX was the are prevalence seems better of XX hours sleep of

So to distinguish. And narcolepsy seems then of a seem a hard two time. without lot patients type IH that to, long hard it just sleep there's there's the patients with

in just I'm get to trying IH a you XX,XXX this feel segment XX,XXX. that So how for diagnosed you patients discuss? to

John C. Jacobs

to why take don’t that Dayno you question Francois. Jeff from

Jeffrey M. Dayno

good the Based of epidemiology, patients. to the the ICSD morning Yeah, criteria so so range think in diagnosed question. XX,XXX thanks data for terms Yeah, of claims starts XX,XXX patients. Franc, and it of in the terms on of I number in IH with

spectrum in medicine along Going an the alluding up terms point, type think two, broader a a there you sleep of epidemiology, patients the XX,XXX you're U.S. some it's terms hypersomnia IH. potentially or with literature the and in raise it's community, type another narcolepsy, of then And good is idiopathic discussion, patients to in XX,XXX IH a in exists one through to And obviously hypersomnolence, active TX. continuum I within central as that especially and of overlap to, of disorder it

took long sleep of you the it they're diagnosis, ICSD sort And, -- away. by sleep ICSD, patients and between that studies. on time, criteria without. clinicians making differentiate three the clinical the and lean Actually too supported However, diagnosis the those IH with

interesting in clinical And, the many the some the lean criteria patients sleep medicine narcolepsy. in there them of have diagnosis. they per ultimately when they're Obviously, with in ICSD that for of as IH to how formal say patients do they community. our phenotype, also but the we terms the managed terms make their by of it's is then difference of diagnosis is KOLs, clinics, on lot the IH clinicians as in a speaking clinical that trials, So to eligible. of What's be with

mentioned on of we're of the I Pitolisant pursuit in trial So obviously indication. execution focused significant for we opportunity going the INTUNE a think the it's forward. before, And as

Francois Brisebois

you. for helpful. point? of first times really Okay, in is the or something then the lastly, maybe thought not extremely XX be XX samples the or that's for ever script Has this first to not has the terms patient's the out seeming in That's hand. problem be thank And necessary based ever to use on days of at days, a Harmony it free that given

John C. Jacobs

Jeff. ahead Go

Jeffrey Dierks

question. the thanks for Franc, Yeah,

sample more within as over for norms. of were no or I believe waiting question a abandonment that WAKIX other and another most in the do cure. for again, and sample. on And to from getting the is patients benchmarks, are there disorder they're mean, So not patients product expeditious this for any industry was decade is that we away lot having a a saying asked versus that where haven't well so Patients obviously time challenges lifelong have And for chronic not with walking products I I product. is actually neurologic are seen waiting David we their a prescription companies. been earlier

patient pleased get really the hub to WAKIX. excited that about So patients ability help we're results and enhancements making really we're the on and we're And our network. our SP continue within to about

Francois Brisebois

for great. progress. congrats and Thanks me. Okay, the on it That's

John C. Jacobs

Franc. you Thank

Operator

Bioscience first Alright, showing quarter am thank This there further you today's no questions. conference I Harmony does conclude XXXX and are financial call. update

a line have You disconnect now and wonderful day. your may

John C. Jacobs

everyone. you, Thank

Harmony Biosciences (HRMY) 3 May 222022 Q1 Earnings call transcript